Indeed, trastuzumab can reduce the CSC populations of cell lines with moderate HER2 levels by specifically targeting HER2, and when administered early (adjuvant setting), it blocks the growth of tumour xenografts of these cell lines. Here, ERBB2 is linked to neoplasm.